ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Cognition Therapeutics Inc

Cognition Therapeutics Inc (CGTX)

0.7683
0.0075
(0.99%)
At close: 31 January 8:00AM
0.7683
0.00
( 0.00% )
After Hours: 8:45AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.7683
Bid
0.75
Offer
0.7575
Volume
2,411,970
0.71 Day's Range 0.815
0.34 52 Week Range 3.44
Market Cap
Previous Close
0.7608
Open
0.79
Last Trade
15
@
0.7482
Last Trade Time
08:43:29
Financial Volume
US$ 1,856,194
VWAP
0.769576
Average Volume (3m)
8,338,630
Shares Outstanding
41,547,995
Dividend Yield
-
PE Ratio
-1.24
Earnings Per Share (EPS)
-0.62
Revenue
-
Net Profit
-25.79M

About Cognition Therapeutics Inc

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an o... Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Camden, Delaware, USA
Founded
-
Cognition Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CGTX. The last closing price for Cognition Therapeutics was US$0.76. Over the last year, Cognition Therapeutics shares have traded in a share price range of US$ 0.34 to US$ 3.44.

Cognition Therapeutics currently has 41,547,995 shares in issue. The market capitalisation of Cognition Therapeutics is US$31.61 million. Cognition Therapeutics has a price to earnings ratio (PE ratio) of -1.24.

CGTX Latest News

This Biotech Is Already Off To The Races Before The Opening Bell

A New York-based biotech is stealing the premarket show leading up to the opening bell after the company announced topline results which met its primary endpoint of safety and To read the full...

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0274-3.443508860120.79570.7987990.6966998250.74540709CS
40.068199.739898016030.700110.8992990.6612757820.77169194CS
120.258350.64705882350.511.290.37583386300.57818606CS
26-0.3317-30.15454545451.11.290.3439913620.58655481CS
52-1.5617-67.0257510732.333.440.3422095340.69465372CS
156-2.6717-77.66569767443.446.26860.348479170.94173412CS
260-11.3817-93.676543209912.1513.80.347792981.06299039CS

CGTX - Frequently Asked Questions (FAQ)

What is the current Cognition Therapeutics share price?
The current share price of Cognition Therapeutics is US$ 0.7683
How many Cognition Therapeutics shares are in issue?
Cognition Therapeutics has 41,547,995 shares in issue
What is the market cap of Cognition Therapeutics?
The market capitalisation of Cognition Therapeutics is USD 31.61M
What is the 1 year trading range for Cognition Therapeutics share price?
Cognition Therapeutics has traded in the range of US$ 0.34 to US$ 3.44 during the past year
What is the PE ratio of Cognition Therapeutics?
The price to earnings ratio of Cognition Therapeutics is -1.24
What is the reporting currency for Cognition Therapeutics?
Cognition Therapeutics reports financial results in USD
What is the latest annual profit for Cognition Therapeutics?
The latest annual profit of Cognition Therapeutics is USD -25.79M
What is the registered address of Cognition Therapeutics?
The registered address for Cognition Therapeutics is 2140 S DUPONT HWY, KENT, CAMDEN, DELAWARE, 19934
What is the Cognition Therapeutics website address?
The website address for Cognition Therapeutics is www.cogrx.com
Which industry sector does Cognition Therapeutics operate in?
Cognition Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TDTHTrident Digital Tech Holdings Ltd
US$ 1.68
(76.84%)
329.24k
KITTNauticus Robotics Inc
US$ 2.0798
(33.32%)
4.81M
ENVBEnveric Biosciences Inc
US$ 4.85
(24.36%)
1.19M
CIFRCipher Mining Inc
US$ 5.63
(19.79%)
3.18M
TEAMAtlassian Corporation PLC
US$ 309.76
(16.04%)
698.98k
ACONAclarion Inc
US$ 7.36
(-12.38%)
245.8k
NAOVNanoVibronix Inc
US$ 0.531
(-10.00%)
485.7k
BHILBenson Hill Inc
US$ 3.61
(-8.61%)
1.64M
FOXXFoxx Development Holdings Inc
US$ 5.90
(-7.67%)
96.34k
CAMPCAMP4 Therapeutics Corporation
US$ 5.50
(-6.78%)
311
NVDANVIDIA Corporation
US$ 123.15
(-1.20%)
24.91M
CLEUChina Liberal Education Holdings Ltd
US$ 0.154
(3.91%)
11.26M
INTCIntel Corporation
US$ 20.32
(1.55%)
11.1M
KITTNauticus Robotics Inc
US$ 2.0798
(33.32%)
4.81M
AAPLApple Inc
US$ 237.70
(0.05%)
3.47M

CGTX Discussion

View Posts
tw0122 tw0122 9 hours ago
Dementia setting in at .79 with some volume 
👍️0
glenn1919 glenn1919 1 month ago
cgtx....................https://stockcharts.com/h-sc/ui?s=cgtx&p=W&b=5&g=0&id=p86431144783
👍️0
Timing101 Timing101 1 month ago
$CTGX Major volume today , Closed in the Green , Low Float , Superbowl Mgt Team and Background in Pharm Launch companies. Positive results in Phase 2 Dementia Testing . See Links (I always provide) below.
8-K today , see attached Company overview
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001455365/000110465924129619/tm2431405d1_8k.htm
-
Presentation from 8-K filed today
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001455365/000110465924129619/tm2431405d1_8k.htm
--
Mgt Team see Bio's ( click on pictures)
https://cogrx.com/about-us/management-team/?_gl=1*nfhroy*_ga*MzEwMDgyNjc3LjE3MzQ1NTUyNjc.*_ga_CKK85WMQ6P*MTczNDU1NTI2Ny4xLjEuMTczNDU1NTM0NS4wLjAuMA..
--
PR out on Testing results
https://www.globenewswire.com/news-release/2024/12/18/2998947/0/en/Cognition-Therapeutics-Announces-Positive-Results-in-Phase-2-Study-of-CT1812-in-Dementia-with-Lewy-Bodies.html
👍️ 2
tw0122 tw0122 1 month ago
$1.24 + 172%
👍️0
tw0122 tw0122 1 month ago
CGTX $1.16
👍️0
tw0122 tw0122 1 month ago
$1.08 + 152%
👍️0
tw0122 tw0122 1 month ago
.98 + 115%
👍️0
tw0122 tw0122 1 month ago
.92 + 102%
👍️0
tw0122 tw0122 1 month ago
.84 + 80%
👍️0
tw0122 tw0122 1 month ago
Flip some more .80
👍️0
tw0122 tw0122 1 month ago
.45 cent shares flipping some now .70
👍️ 1
Guzzi62 Guzzi62 2 months ago
Opened a small position here at 0.38
👍 1
glenn1919 glenn1919 2 months ago
CGTX...........................https://stockcharts.com/h-sc/ui?s=CGTX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 2 months ago
.69 still going 34m float watch .76 resistance probably max gain. But if it breaks it .90 possible 
👍️0
tw0122 tw0122 2 months ago
Flip rest at .5970
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
DILUTE INTO FLUFF NEWS
👍️0
tw0122 tw0122 2 months ago
.58 flipping half from .47 
👍️0
tw0122 tw0122 2 months ago
.53 “We now have evidence that the dramatic reduction of cognitive decline that was sustained over 6 months in patients treated with CT1812 who had lower plasma p-tau217 levels also was associated with improvements in key indicators of brain cell function. This finding gives us confidence that CT1812 is having a disease-modifying effect,” explained Anthony O. Caggiano, MD, PhD, Cognition’s C
👍 1
tw0122 tw0122 2 months ago
.47 . - Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology -
👍 2
Imokhopeur Imokhopeur 4 months ago
More attention here is on the way, imo.
👍️0
Imokhopeur Imokhopeur 4 months ago
I’m in
👍️0
Monksdream Monksdream 6 months ago
CGTX new 52. Week low
👍️0
Awl416 Awl416 6 months ago
T1 halt….
👍️0
Monksdream Monksdream 6 months ago
No news
https://ih.advfn.com/markets/nasdaq/premarket
👍️0
Monksdream Monksdream 6 months ago
CGTX under $3
👍️0
Monksdream Monksdream 6 months ago
Whoops, I did it, again
👍️0
Monksdream Monksdream 6 months ago
CGTX under $2
👍️0
dannyzee84 dannyzee84 8 months ago
Great stock. Future is bright. Bags packed.
👍️0
Monksdream Monksdream 9 months ago
CGTX under $2
👍️0
Monksdream Monksdream 11 months ago
CGTX under $2
👍️0
Monksdream Monksdream 11 months ago
CGTX under $2
👍️0
Monksdream Monksdream 1 year ago
CGTX new 52 week low
👍️0
Monksdream Monksdream 1 year ago
CGTX under $2
👍️0
artfulife artfulife 2 years ago
Is that a wild guess or is there some reasoning behind your statement?
👍️0
willlbone willlbone 2 years ago
Time to buy.
👍️0
crudeoil24 crudeoil24 2 years ago
Great! I believe we'll do quite well on share price surge!
👍️ 1
tw0122 tw0122 2 years ago
Already been here for a few weeks …lol. One of my very few longer term hold OTC plays.
Thanks..
👍️0
crudeoil24 crudeoil24 2 years ago
Nice "pop" on FDA phase II news! If you have time, you may want to check out GDVM. Symbol change happening any day. Two hours of reading you'll be buying shares.
👍️0
tw0122 tw0122 2 years ago

The START study is supported by a grant of approximately $81 million for 5 years from the National Institutes of Health’s (NIH) National Institute on Aging (NIA) to accelerate development of new therapies for Alzheimer’s disease.

“The START study and ACTC represent some of the many ways that NIA funds research into novel therapeutics for treating Alzheimer's and related dementias,” stated Laurie Ryan, Ph.D., an NIA clinical research program official.

“We appreciate the continued support of the NIA, which has been an important partner in our work to develop CT1812. Our lead drug candidate is a potentially disease-modifying oral therapeutic for the treatment of Alzheimer's disease and other neurodegenerative conditions,” added Cognition president and CEO, Lisa Ricciardi. “With the NIA's funding, we have been able to complete a series of preclinical and clinical trials, thus advancing our understanding of CT1812 and the role of the sigma-2 (s-2) receptor in Alzheimer’s disease. We look forward to recruiting patients for the START study with our collaboration partners at the ACTC.”

“ACTC aims to accelerate Alzheimer’s drug development, working with academic and industry partners,” said Paul Aisen, M.D., professor of neurology at the University of Southern California and director of the Alzheimer's Therapeutic Research Institute. “The START study is an important component of ACTC efforts. Having an authorized protocol for the START study is a critical step in preparing to open clinical sites for the trial by mid-2023.”

NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has cleared the U.S. Food and Drug Administration comment period and may now proceed with the 540-patient Phase 2 START study of CT1812 in adults with mild cognitive impairment or early Alzheimer’s disease. This randomized placebo-controlled trial will be conducted at approximately 50-to-60 sites in North America including those premier institutions in the Alzheimer's Clinical Trials Consortium (ACTC). CT1812 is an investigational oral small molecule that binds to a receptor on synapses and is designed to prevent the toxic effects of soluble beta amyloid (Aß) oligomers on neurons, which drive the progression of neurodegenerative diseases such as Alzheimer’s disease.


“The initial clinical results observed with CT1812 are encouraging and we look forward to advancing it into the START trial to evaluate its effects in a larger study in people with early Alzheimer’s disease,” said Christopher H. van Dyck, M.D., director of the Yale Alzheimer's Disease Research Center and primary investigator of the START study. “We envision a future with multiple treatment options, to be used alone or in combination according to evidence, to achieve the greatest slowing of Alzheimer's disease progression.”
👍 1
anderson800 anderson800 2 years ago
Chart is looking better all of the time. The 50 day MA is only about 15 cents away from the 200 day and when we get the golden cross that should trigger a lot of buy signals.
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 2 years ago
$CGTX Love the chart..looking for continuation next week..

https://stockcharts.com/c-sc/sc?s=CGTX&p=D&b=5&g=0&i=0&r=1669471320227
👍️ 1
anderson800 anderson800 2 years ago
Hopefully this has seen its low and now is starting a new uptrend. I just grabbed my first 1000 shares today after seeing the CEO added 71,000 shares.
👍️0
turning stone turning stone 2 years ago
Nope but not any major loss.
👍️0
Pedro2004 Pedro2004 2 years ago
Were you able to get-out with a profit today?
👍️0
turning stone turning stone 3 years ago
While the stock is dropping on no relative news it is a good time to think about purchasing more shares. I have been averaging down and would not mind $2.00/share to bring me more in line with what makes me comfortable.
👍️0
turning stone turning stone 3 years ago
As a new investor in CGTX I look forward to new and interesting posts on the board. I am tired of plain B-S from those who get off on seeing there jibber in print.
👍️0
turning stone turning stone 3 years ago
Hope there is very little shorting done to this stock!!!!!
👍️0
turning stone turning stone 3 years ago
Hopefully we have a winner by end of this year.
👍️0
turning stone turning stone 3 years ago
I hope in the Mid 3's is a good starting point
👍️0
turning stone turning stone 3 years ago
As a new shareholder I fit the need going to be 77.
👍️0

Your Recent History

Delayed Upgrade Clock